Advancing Mechanistically Relevant Potency Assessment Through Functional Disease Models

• Navigating updated guidance for mechanistically relevant potency assays
• Addressing the challenge of measuring potency for cell therapies with multifactorial mechanisms of action
• Deconstructing Mechanism of Action (MoA) via disease modeling
• Translating biology into quantifiable bioassays using new approach methodologies (NAMs)

Speakers:

Caryn Cloer

Principal Scientist

ProKidney